Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Chenye Wang, Jia Yu, Caifei Ding & Chunyue Chen. (2023) CangFu Daotan decoction improves polycystic ovarian syndrome by downregulating FOXK1. Gynecological Endocrinology 39:1.
Read now
Read now
Articles from other publishers (6)
Yanhong Fu, Pengpeng Xie, Qingping Yang, Peng Chen & Jingwei Yu. (2024) Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome. Prostaglandins & Other Lipid Mediators 170, pages 106801.
Crossref
Crossref
Weihuan Hu, Ningning Xie, Hanyue Zhu, Yiting Jiang, Sijia Ding, Shaoyan Ye, Siwen Zhang, Fangfang Wang, Fan Qu & Jue Zhou. (2024) The effective compounds and mechanisms of Cang-Fu-Dao-Tan Formula in treating polycystic ovary syndrome based on UPLC/Q-TOF-MS/MS, network pharmacology and molecular experiments. Journal of Pharmaceutical and Biomedical Analysis 239, pages 115867.
Crossref
Crossref
Kenneth Maiese. (2023) Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK. Cells 12:22, pages 2595.
Crossref
Crossref
Kenneth Maiese. (2023) The impact of aging and oxidative stress in metabolic and nervous system disorders: programmed cell death and molecular signal transduction crosstalk. Frontiers in Immunology 14.
Crossref
Crossref
Kexin Wang & Yanhua Li. (2023) Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome. Frontiers in Endocrinology 14.
Crossref
Crossref
Achsha Babu & Gnanasambandan Ramanathan. (2023) Multi-omics insights and therapeutic implications in polycystic ovary syndrome: a review. Functional & Integrative Genomics 23:2.
Crossref
Crossref